The goal of this study is to evaluate autologous MSCs as an alternative for antibody induction therapy in renal transplantation.
Renal transplantation is the most common and successful type of organ transplantation. Induction therapy with antibody plus the maintenance immunosuppressive agents have greatly improved graft survival in renal transplantation. Since mesenchymal stem cells(MSCs)have been used successfully to treat graft versus host disease and show immune modulation function both in vitro and in vivo and may help in repairing damaged tissue(s), we evaluate autologous MSCs as an alternative for antibody induction therapy. Moreover, we examine if MSCs could improve the recovery of early function in transplanted kidney.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
165
Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
kidney transplantation with standard immunosuppressive treatment regime
Stem cell therapy center,Fuzhou General Hospital
Fuzhou, Fujian, China
Incidence rate of biopsy-proven acute rejection and early renal function recovery
Time frame: At 1 year post-transplant
Patient and graft survival and prevalence of adverse events
Time frame: At 1 year post-transplant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.